Capricor Therapeutics faces a class action lawsuit alleging it made false statements about the progress of its drug deramiocel towards FDA approval. The lawsuit claims the company misled investors by promoting positive trial results while knowing of adverse data from its Phase 2 HOPE-2 trial. Shareholders who bought Capricor shares between October 9, 2024, and July 10, 2025, are encouraged to join the case to recover losses. There is no cost to participate, and the law firm will provide updates throughout the case.
Capricor Therapeutics faces a class action lawsuit alleging securities law violations. For readers following health-sector stocks, here is Pluang's market snapshot as of Sep 22, 2026 12:31 WIB: out of 95 priced US health stocks, 43 rose and 49 fell. Notable movers include HRTX at USD 0.30 with a 1-day change of +11.11% and typical hold time of 34 days, BNGO at USD 1.89 with a 1-day change of +9.25% and 90% sell order activity, and DGX at USD 234.00 with a 1-day change of -5.06% and typical hold time of 55 days.
UBS Group AG has officially notified that it holds 7,768,727 shares in Bang & Olufsen A/S, representing 5.27% of the company's total share capital and voting rights as of October 9, 2026. This disclosure is made in compliance with the Danish Capital ...
On October 14, 2026, Michael Brierley, a Non-Executive Director of Admiral Group plc, and his wife Rachel Brierley acquired shares of the company through a dividend reinvestment trading plan. The transactions involved purchasing ordinary shares at pr...
Norsk Hydro will publish its third-quarter 2026 financial results on October 23, 2026, at 07:00 CEST. The company's CEO and CFO will present the results via a live webcast at 08:30 CEST the same day, allowing investors to ask questions online. There ...
The FDA has approved Roche's Enspryng (satralizumab) as the first and only at-home subcutaneous treatment for adults with thyroid eye disease (TED). This approval follows positive results from Phase III SatraGO-2 trials showing significant reductions...
NEAR Protocol's price surged over 12% in 24 hours, trading above $5.20 following the appointment of Helius CEO Mert Mumtaz to the NEAR Foundation Council. This move supports governance as the Foundation expands privacy and cross-chain trading feature...
